

# MANKIND CORP

## **FORM 8-K** (Current report filing)

Filed 08/07/17 for the Period Ending 08/07/17

|             |  |
|-------------|--|
| Address     | 25134 RYE CANYON LOOP<br>SUITE 300<br>VALENCIA, CA 91355 |
| Telephone   | 6617755300   |
| CIK         | 0000899460   |
| Symbol      | MNKD   |
| SIC Code    | 2834 - Pharmaceutical Preparations                       |
| Industry    | Biotechnology & Medical Research                         |
| Sector      | Healthcare   |
| Fiscal Year | 12/31  |

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT**  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934

**Date of Report (Date of earliest event reported): August 7, 2017**

---

**MannKind Corporation**

( Exact name of Registrant as specified in its charter )

---

**Delaware**  
(State or other jurisdiction of  
incorporation or organization)

**000-50865**  
(Commission  
File Number)

**13-3607736**  
(IRS Employer  
Identification No.)

**25134 Rye Canyon Loop, Suite 300**  
**Valencia, California**  
(Address of principal executive offices)

**91355**  
(Zip Code)

**Registrant's telephone number, including area code: (661) 775-5300**

**N/A**  
(Former name or former address, if changed since last report.)

---

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. of Form 8-K):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

---

**Item 8.01 Other Events.**

On August 4, 2017, the board of directors of MannKind Corporation (“MannKind”) resolved to voluntarily delist its common stock from The Tel Aviv Stock Exchange Ltd., or TASE. Under applicable Israeli law, the delisting of MannKind’s common stock from trading on the TASE is expected to become effective three months from the date of request. During this time, MannKind’s common stock will continue to be traded on the TASE.

MannKind’s common stock continues to be listed for trading on The NASDAQ Global Market, or NASDAQ, and all shares of common stock traded on the TASE are expected to transfer to NASDAQ once the delisting of MannKind’s common stock from the TASE becomes effective.

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: August 7, 2017

**MANKIND CORPORATION**

By: /s/ David Thomson

Name: David Thomson, Ph.D., J.D.

Title: Corporate Vice President, General Counsel and Secretary